Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update

被引:41
作者
Kats, Suzanne [1 ]
Schonberger, Jacques P. A. M. [1 ]
Brands, Ruud [2 ]
Seinen, Willem [2 ]
van Oeveren, Wim [3 ]
机构
[1] Catharina Hosp, Dept Cardiothorac Surg, NL-5602 ZA Eindhoven, Netherlands
[2] Univ Utrecht, Inst Risk Assessment, Utrecht, Netherlands
[3] Univ Med Ctr Groningen, Dept Biomed Engn, Groningen, Netherlands
关键词
Endotoxin release; Cardiopulmonary bypass; Inflammatory response syndrome; ANTIENDOTOXIN CORE ANTIBODIES; IMMOBILIZED HEMOPERFUSION CARTRIDGE; INTESTINAL ALKALINE-PHOSPHATASE; SYSTEMIC INFLAMMATORY RESPONSE; CYTOKINE ACTIVATION; MONONUCLEAR-CELLS; INTRAMUCOSAL PH; HEART-SURGERY; LIPOPOLYSACCHARIDE; PERMEABILITY;
D O I
10.1016/j.ejcts.2010.06.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac surgery with cardiopulmonary bypass provokes a systemic inflammatory response syndrome caused by the surgical trauma itself, blood contact with the non-physiological surfaces of the extracorporeal circuit, endotoxemia, and ischemia. The role of endotoxin in the inflammatory response syndrome has been well investigated. In this report, we reviewed recent advances in the understanding of the pathophysiology of the endotoxin release during cardiopulmonary bypass and the possible therapeutic strategies aimed to reduce the endotoxin release or to counteract the inflammatory effects of endotoxin. Although many different strategies to detoxify endotoxins were evaluated, none of them were able to show statistically significant differences in clinical outcome. (C) 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:451 / 458
页数:8
相关论文
共 63 条
[1]  
ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115
[2]   Endotoxemia in coronary artery bypass surgery: A comparison of the off-pump technique and conventional cardiopulmonary bypass [J].
Aydin, NB ;
Gercekoglu, H ;
Aksu, B ;
Ozkul, V ;
Sener, T ;
Kiygil, I ;
Turkoglu, T ;
Cimen, S ;
Babacan, F ;
Demirtas, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (04) :843-848
[3]  
Baek L, 1980, Ugeskr Laeger, V142, P1405
[4]  
BARCLAY GR, 1995, BACTERIAL ENDOTOXINS, P263
[5]   Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota [J].
Bates, Jennifer M. ;
Akerlund, Janie ;
Mittge, Erika ;
Guillemin, Karen .
CELL HOST & MICROBE, 2007, 2 (06) :371-382
[6]   A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass [J].
Bennett-Guerrero, Elliott ;
Grocott, Hilary P. ;
Levy, Jerrold H. ;
Stierer, Kevin A. ;
Hogue, Charles W. ;
Cheung, Albert T. ;
Newman, Mark F. ;
Carter, Alison A. ;
Rossignol, Daniel P. ;
Collard, Charles D. .
ANESTHESIA AND ANALGESIA, 2007, 104 (02) :378-383
[7]  
BennettGuerrero E, 1997, JAMA-J AM MED ASSOC, V277, P646
[8]   Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide [J].
Bentala, H ;
Verweij, WR ;
Huizinga-Van der Vlag, A ;
van Loenen-Weemaes, AM ;
Meijer, DKF ;
Poelstra, K .
SHOCK, 2002, 18 (06) :561-566
[9]   Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets [J].
Beumer, C ;
Wulferink, M ;
Raaben, W ;
Fiechter, D ;
Brands, R ;
Seinen, W .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) :737-744
[10]  
BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318